• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Scaling across Series A to C

September 30, 2021 by David Barret Leave a Comment

Arthur Nobel
Contributor

Share on Twitter

Arthur Nobel is an entrepreneur turned investor, now working as principal at Knight Capital in Amsterdam, specializing in scaling companies. He started his career at Rocket Internet before holding various growth roles across Europe. Co-author of the book “Leaders of Growth,” he also hosts its related podcast.

The T2D3 (triple, triple, double, double, double) acronym has become a well-known goal in the startup scene for achieving unicorn status. Formulating the goal can be easy, but realizing such tremendous revenue growth is notoriously difficult.

A study from Dealroom shows that about 16% of the companies that raise a seed round manage to raise a Series B investment, and only about 7% of those that raise seed funding raise a Series C investment.

This statistic is partially explained by a lack of a good organizational framework for scaling companies across seed to Series C. There is a lot of great content on the startup phase (getting to product-market fit) and success stories (raising hundreds of millions of dollars and multibillion dollar exits), but there is little available on how founders can grow a company from $1 million to $25 million in annual revenues (broadly defined as the Series A, B and C stages).

Based on 47 interviews with industry experts including Sean Ellis, Mark Roberge, Bill Macaitis, Micha Breakstone and Brian Requarth, desk research and our own experience as founders and investors in Series A to C companies, we have derived three major insights about how to scale a company from the organizational perspective. Here’s our framework:

Scaling is a continuum with maturity stages

A fast-scaling company with revenue of $5 million revenue has different scaling needs compared to a fast-scaling startup with $15 million in revenue. The concept of “maturity stages” for scaling a company can be useful to address the different needs.

The most common “maturity stages” of scaling a company are:

  • Ad hoc.
  • Basic process.
  • Repeatable process.
  • Predictable process.
  • At scale.

Image Credits: Knight Capital

Typically, for a seed-stage company, everything is developed in a more or less ad-hoc manner. At the Series A stage, it’s more about developing repeatable processes. Series B and C are about predictability of outcomes. Beyond Series C, it’s about doing everything at scale.

Of course, this is a companywide view. As we argue below, this can be different for individual departments. For example, a company at a “repeatability” stage that generates inbound leads through digital marketing efforts and has an enterprise sales department will often have a much more mature marketing department compared to sales.

The takeaway is to initially figure out in which stage your company and departments are in and only do what is required for that stage.

The challenges to scaling

You scale a company, from an organizational perspective, by overcoming numerous challenges. We believe that these challenges can be largely categorized into five buckets:

  1. KPIs and data.
  2. People.
  3. Documentation and enablement.
  4. Processes.
  5. Tooling.

We believe it is best to approach these challenges on the departmental and subdepartmental levels to make it workable.

KPIs and data

Data-informed decision-making is particularly important in the T2D3 journey. It is important to realize that different KPIs are relevant at different stages. First, focus on the right metrics for your stage. An LTV:CAC metric (lifetime value to acquisition costs) is less relevant for a seed company than retention.

Source Link Scaling across Series A to C

David Barret
David Barret

Related posts:

  1. Kuwait starts to recycle massive tyre graveyard
  2. Cryptocurrencies selloff widens: Bitcoin down nearly 4%, ether 6%
  3. UK will be ‘hard-headed’ in defending interests, foreign minister says of security deal
  4. France cancels defence meeting with UK over submarine row, sources say

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Are There Body Parts You Can Live Without? Find Out More In Issue 37 Of CURIOUS – Out Now
  • New Study Unearths Humanity’s “Hidden” Crossings Out Of Africa
  • Trichonephila Clavipes: The Spider That Spins “Golden” Silk
  • The Southern Delta Aquariids And Alpha Capricornids Meteor Showers Will Dazzle The Skies Together Soon
  • Virus Found In Black-Eyed Pea Plants Could Be Used To Treat Cancer
  • Many People Have No Idea Where Oil Actually Comes From. It’s Not Dinosaurs
  • “World’s Rarest Elephant”: Meet Motty, The Only Known Elephant Hybrid
  • Missing 40 Percent Of Matter In The Universe Finally Discovered, Could We Be On Track For A Universal Cancer Vaccine, And Much More This Week
  • Solar Power Producing Heliostats Could Get A “Night Job” Finding Asteroids
  • COVID-19 Can Lead To Build Up Of Alzheimer’s-Linked Protein Clumps In Eyes And Brain
  • The Wild Life Of Snowflake, The Only Albino Gorilla Ever Known
  • Stunning Drone Footage Reveals Largest Turtle Nesting Site In The World, Containing 41,000 Females
  • New “Different Form” Of Type 1 Diabetes Found In Sub-Saharan African And Black American Patients
  • Neanderthals May Have Feasted On Maggots, Which They Harvested From Rotting Flesh
  • Common Cannabis Substitute May Be Far More Psychoactive Than Previously Thought
  • This Is The Most Bizarre International Border In The World
  • Earth Will Not Fall Into Darkness Next Week – But There Is An “Eclipse Of The Century” In 2027
  • 850,000-Year-Old Remains Suggest Prehistoric Child Was Decapitated And Eaten By Its Own Kind
  • How To Watch The ISS As It Crosses The US Night Sky In The Next Few Days
  • “Robo-Bunnies” Are Florida’s Newest Weapon Against Python Invaders
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version